Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report

Cover Page

Cite item

Full Text

Abstract

Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoimmunotherapy in clinical practice. Chemotherapy based on durvalumab in comparison with the standard chemotherapy demonstrated the statistically and clinically significant increase in median overall survival in patients with previously untreated ES-SCLC in the CASPIAN international trial. This article deals with the case of the application of standard chemotherapy in combination with durvalumab as a first-line ES-SCLC therapy. The patient started receiving durvalumab therapy in June 2017 as a part of the CASPIAN international trial. In March 2021 the duration of therapy was 45 months, the patient had a complete regression of the disease.

About the authors

Albina S. Zhabina

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Aid (oncological)

Author for correspondence.
Email: albina_zhabina@inbox.ru
ORCID iD: 0000-0001-9749-8519
SPIN-code: 1724-7764

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Fedor V. Moiseenko

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Aid (oncological); Petrov National Medical Research Center of Oncology; Mechnikov North-Western State Medical University

Email: moiseenkofv@gmail.com
ORCID iD: 0000-0003-2544-9042

D. Sci. (Med.)

Russian Federation, Saint Petersburg; Saint Petersburg; Saint Petersburg

Nikita M. Volkov

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Aid (oncological)

Email: volkovnm@gmail.com
ORCID iD: 0000-0002-6232-257X

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Nuriniso Kh. Abduloeva

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Aid (oncological)

Email: Abduloeva-n@mail.ru
ORCID iD: 0000-0001-5236-0241

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Vladimir M. Moiseenko

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Aid (oncological)

Email: moiseyenkov@gmail.com
ORCID iD: 0000-0002-2246-0441

D. Sci. (Med.), Prof.

Russian Federation, Saint Petersburg

References

  1. Bychkov MB. Small cell lung cancer: status of the problem in 2013 and changes in the last 40 years. Malignant tumours. 2013;1:28-34. doi: 10.18027/2224-5057-2013-1-28-34
  2. Zikos E, Ghislain I, Coens C, et al. Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. Lancet Oncol. 2014;15(2):e78-e89. doi: 10.1016/S1470-2045(13)70493-5
  3. Soomro Z, Youssef M, Yust-Katz S, et al. Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis. 2020;12(10):6253-63. doi: 10.21037/jtd.2020.03.88
  4. Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-61. doi: 10.1038/nrclinonc.2017.71
  5. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69-79. doi: 10.21037/tlcr.2018.01.16
  6. Zhou T, Zhang Z, Luo F, et al. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2020;3(10):e2015748. doi: 10.1001/jamanetworkopen.2020.15748
  7. Paz-Ares L, Dvorkin M, Chen Y, et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-39. doi: 10.1016/S0140-6736(19)32222-6
  8. Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8
  9. Goldman JW, Garassino MC, Chen Y, et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020;149:46-52. doi: 10.1016/j.lungcan.2020.09.003

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Histological image of the specimen of the material received from Patient A.

Download (175KB)
Indexing metadata
3. Fig. 2. Multispiral computed tomography (MCT) before the therapy (June 2017). Centrally located right lung cancer with the lesion on the right lower lobe bronchus with the damage of the middle lobe bronchus and the primary bronchi. Intrathoracic lymph nodes metastases, it is not inconceivable that the damage took the area of bifurcation of the trachea, the right pulmonary artery. Inorganic abdominal mass – peritoneal carcinomatosis.

Download (139KB)
Indexing metadata
4. Fig. 3. MCT, August 2017. Centrally located right lung cancer with intrathoracic lymph nodes metastases. There is a partial regression of the disease by comparison with MCT of June 2017.

Download (126KB)
Indexing metadata
5. Fig. 4. MCT – November 2017 by comparison with MCT – June 2017.

Download (232KB)
Indexing metadata
6. Fig. 5. Computed tomography of the chest: the regression of right-sided lower lobe bronchopneumonia.

Download (101KB)
Indexing metadata
7. Fig. 6. The response to therapy in follow-up control.

Download (311KB)
Indexing metadata
8. Fig. 7. The duration of the response to therapy in the CASPIAN trial. The experience of Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Aid (oncological).

Download (35KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies